Treatment of Anxiety and Insomnia

Introduction to Treatment Options

• The American Academy of Sleep Medicine recommends initiating a short-intermediate acting benzodiazepine receptor agonist for insomnia while simultaneously starting sertraline for anxiety, combined with cognitive behavioral therapy for insomnia (CBT-I) 1, 2, 3

Pharmacological Treatment Options

• The American Academy of Sleep Medicine suggests sertraline as the next medication trial after citalopram intolerance, due to different side effect profiles despite similar mechanisms 4
• The American Academy of Sleep Medicine recommends starting sertraline at a low dose and gradually titrating to minimize initial side effects 5
• Venlafaxine can be considered if sertraline is ineffective, as it has demonstrated superior efficacy for anxiety compared to some SSRIs 5
• Mirtazapine is an alternative option that can address both anxiety and insomnia through its sedating properties 6, 5
• Short-intermediate acting benzodiazepine receptor agonists are first-line pharmacological treatments for insomnia 1, 2
• Ramelteon is an alternative that works differently than previously tried medications 1, 2
• Low-dose doxepin is FDA-approved for insomnia and works through a different mechanism than amitriptyline 1, 3

Non-Pharmacological Approaches

• Cognitive Behavioral Therapy for Insomnia (CBT-I) should be implemented concurrently with any pharmacological treatment 1, 2, 3
• CBT-I includes sleep restriction, stimulus control, cognitive therapy, and sleep hygiene education 2, 3
• Multicomponent therapy without cognitive elements is also effective and recommended 2

Treatment Algorithm

• Initiate CBT-I and sertraline simultaneously 1, 2, 3
• Add a short-intermediate acting BzRA for acute insomnia relief 1, 2
• If sertraline is ineffective or poorly tolerated, switch to mirtazapine 6, 5
• If insomnia persists, consider ramelteon or low-dose doxepin 1, 2

Monitoring and Follow-up

• Assess effectiveness, side effects, and adherence every 2-4 weeks initially 1, 2
• Monitor for potential drug interactions and evaluate sleep patterns using sleep logs 6
• Employ the lowest effective maintenance dosage and taper medication when conditions allow 1, 2

Important Considerations

• Avoid over-the-counter antihistamines or herbal supplements as they lack efficacy and safety data for chronic insomnia 1, 2
• Medication tapering and discontinuation are facilitated by concurrent CBT-I 1, 2
• Patient education regarding treatment goals, safety concerns, potential side effects, and rebound insomnia is essential 1, 2
• Long-term pharmacotherapy may be indicated for severe or refractory cases, but should include regular follow-up and monitoring 1, 2